Johnson & Johnson has agreed to acquire Intra-Cellular Therapies, a Bedminster, New Jersey-based bio/pharmaceutical company focused on the development of therapeutics for central nervous system disorders, for $14.6 billion. 

A key asset in the deal is Intra-Cellular Therapies’ Caplyta (lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate. The drug is also being reviewed as an adjunctive treatment for major depressive disorder with a supplemental new drug application submitted to the US Food and Drug Administration for this indication. The acquisition also includes ITI-1284, a Phase II compound being studied in generalized anxiety disorder and Alzheimer’s disease-related psychosis and agitation. 

Under the agreement, Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies for a payment of $132.00 per share in cash. The closing of the transaction is expected to occur later in 2025, subject to applicable regulatory approvals, approval by Intra-Cellular Therapies’ stockholders, and other customary closing conditions.  

Source: Johnson & Johnson